​

Funding Round

Series B - Brixton Biosciences

Series B - Brixton Biosciences

Investment Firm

Overview

Brixton Biosciences is a clinical-stage life sciences company that develops novel therapies for treating pain.

Announced Date

May 14, 2024

Closed on Date

May 14, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Schooner Capital

Schooner Capital

Schooner Capital is a early_stage_venture and late_stage_venture and private_equity and seed firm.

Participant Investors

6

Investor Name
Participant InvestorSparta Group
Participant InvestorExcelestar Ventures
Participant InvestorCatalyst Health Ventures
Participant InvestorSchooner Capital
Participant InvestorSV Health Investors

Round Details and Background

Brixton Biosciences raised $33000000 on 2024-05-14 in Series B

Brixton Biosciences is a clinical-stage life sciences company that develops novel therapies for treating pain.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 01, 2021
Venture Round - Brixton Biosciences
2-undefined
May 14, 2024
Series B - Brixton Biosciences
6-33.0M

Recent Activity

News

May 31, 2024

Brixton Biosciences Inks $33M in Series B Funding

News

May 15, 2024

brixtonbio.com - Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

News

May 14, 2024

Venture Capital Access Online - Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

News

May 14, 2024

PR Newswire - Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

News

May 14, 2024

FinSMEs - Brixton Biosciences Raises $33M in Series B Funding

News

May 14, 2024

BioSpace - Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain